Search results
Results from the WOW.Com Content Network
(Reuters) -FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca in the United States and certain other territories after the companies agreed to ...
No one likes being given the wrong information. Investors reacted in dismay and sent Fibrogen (FGEN) shares deep into the red following the company's embarrassing announcement. The biotech company ...
Last month, the FDA approved Biogen’s Alezheimer’s disease drug Aducanumab, in a controversial decision that went against the advisory committee’s recommendation. When looking at the case of ...
Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells.
Several HIF-PHIs, including roxadustat, daprodustat, vadadustat, molidustat, and enarodustat, have been approved in various countries for the treatment of renal anemia. [3] [4] While these drugs have demonstrated promising results in clinical trials, ongoing research is focused on evaluating their long-term safety profile, particularly regarding cardiovascular outcomes, thromboembolic events ...
The stock of FibroGen (NAS:FGEN, 30-year Financials) is estimated to be possible value trap, according to GuruFocus Value calculation.
14190 Ensembl ENSG00000127951 ENSMUSG00000039899 UniProt Q14314 P12804 RefSeq (mRNA) NM_006682 NM_008013 RefSeq (protein) NP_006673 NP_032039 Location (UCSC) Chr 7: 77.19 – 77.2 Mb Chr 5: 21.58 – 21.58 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Fibrinogen-like protein 2, also known as FGL2, is a protein which in humans is encoded by the FGL2 gene. Structure FGL2 is a 439 ...
FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?